DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8jkz6l/papillary_renal) has announced the addition of the "Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" report to their offering.
"Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Papillary Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Papillary Renal Cell Carcinoma.
Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Astellas Pharma Inc.
- National Cancer Institute
- Fox Chase Cancer Center
- Memorial Sloan Kettering Cancer Center
- UNICANCER Group
- Austrian Urogynecology Working Group
- Ohio State University Comprehensive Cancer Center
- Fred Hutchinson Cancer Research Center
- Children's Oncology Group
For more information visit http://www.researchandmarkets.com/research/8jkz6l/papillary_renal.
